Home LiteratureArticle Details
PMID: 8100914 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article

Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen.

Lancet (London, England) ·Vol. 342 ·No. 8863 ·1993-07-10 ·Pages 83-4

Chocair P, Duley J, Simmonds HA, Cameron JS, Ianhez L, Arap S, Sabbaga E

Abstract

Early rejection can still complicate renal transplantation even with cyclosporin. We added low-dose allopurinol (25 mg on alternative days) to "triple" immunosuppression with cyclosporin, prednisolone, and azathioprine for twelve recipients of cadaver renal grafts. The controls were fifteen patients on triple therapy alone. Only one rejection episode occurred among the allopurinol-treated patients, whereas eleven controls had rejections (seven with more than one episode). Allopurinol may be toxic when combined with azathioprine, yet the bone marrow tolerated the new regimen well. As expected, reduction of the azathioprine dose was necessary in the treated group.

MeSH Terms
Allopurinol/administration & dosage Azathioprine/administration & dosage Cyclosporine/administration & dosage Drug Therapy, Combination Female Graft Rejection Humans Immunosuppression Therapy/methods Kidney Transplantation Male Prednisolone/administration & dosage
Chemicals
Allopurinol Cyclosporine Prednisolone Azathioprine
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Chocair P
Renal Transplant Unit, Hospital das Clinicas, Universidade de São Paulo, Brazil.
Duley J
Simmonds H A
Cameron J S
Ianhez L
Arap S
Sabbaga E
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
Published
1993-07-10
Pages
83-4
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com